| |
Control (n = 15)
|
Low Dose (n = 15)
|
High Dose (n = 15)
|
Total (n = 45)
|
|---|
|
Age (years) (mean, SD)
|
55.5 (15.3)
|
57.5 (13.2)
|
53.8 (9.9)
|
55.6 (12.8)
|
|
Surgery Type (N, %)
|
|
Lumpectomy
|
10 (66.7)
|
9 (60.0)
|
10 (66.7)
|
29 (64.4)
|
|
Mastectomy
|
5 (33.3)
|
6 (37.5)
|
5 (33.3)
|
16 (35.5)
|
|
Diagnosis (N, %)
|
|
IDC
|
13 (86.7)
|
13 (86.7)
|
11 (73.3)
|
37 (82.2)
|
|
ILC
|
1 (6.7)
|
2 (13.3)
|
4 (26.7)
|
7 (15.6)
|
|
IMC
|
1 (6.7)
|
0 (0.0)
|
0 (0.0)
|
1 (6.7)
|
|
Primary Tumour Size (cm) (mean, SD)
|
3.1 (1.2)
|
2.7 (0.9)
|
3.3 (2.2)
|
3.0 (1.5)
|
|
Grade (N, %)
|
|
1
|
1 (6.7)
|
1 (6.7)
|
1 (6.7)
|
3 (6.7)
|
|
2
|
4 (26.6)
|
6 (40.0)
|
5 (33.3)
|
15 (33.3)
|
|
3
|
10 (66.7)
|
8 (53.3)
|
9 (60.0)
|
27 (60.0)
|
|
Mitotic Score (N, %)
|
|
1
|
4 (26.7)
|
5 (33.3)
|
5 (33.3)
|
14 (31.1)
|
|
2
|
3 (20.0)
|
3 (20.0)
|
4 (26.7)
|
10 (22.2)
|
|
3
|
8 (53.3)
|
7 (46.7)
|
6 (37.5)
|
21 (46.7)
|
|
ER Status (N, %)
|
|
Positive
|
12 (80.0)
|
12 (80.0)
|
11 (73.3)
|
35 (77.8)
|
|
Negative
|
3 (20.0)
|
3 (20.0)
|
4 (26.7)
|
10 (22.2)
|
|
PR Status (N, %)
|
|
Positive
|
12 (80.0)
|
10 (66.7)
|
10 (66.7)
|
32 (71.1)
|
|
Negative
|
3 (20.0)
|
5 (33.3)
|
5 (33.3)
|
13 (28.9)
|
|
Her2 Status (N, %)
|
|
Positive
|
1 (6.7)
|
4 (26.7)
|
2 (13.3)
|
7 (15.6)
|
|
Negative
|
14 (93.3)
|
11 (73.3)
|
13 (86.7)
|
38 (84.4)
|
|
DCIS Present (N, %)
|
|
Yes
|
12 (80.0)
|
10 (66.7)
|
9 (60.0)
|
31 (68.9)
|
|
No
|
3 (20.0)
|
5 (33.3)
|
6 (37.5)
|
14 (31.1)
|
|
Margin Status (N, %)
|
|
Positive (Invasive)
|
1 (6.7)
|
1 (6.7)
|
4 (26.7)
|
6 (13.3)
|
|
Negative (Invasive)
|
14 (93.3)
|
14 (93.3)
|
11 (73.3)
|
39 (86.7)
|
|
Positive (DCIS)
|
1 (6.7)
|
0 (0.0)
|
1 (6.7)
|
2 (4.4)
|
|
Negative (DCIS)
|
14 (93.3)
|
15 (100)
|
14 (93.3)
|
43 (95.6)
|
|
Revised Margins at Index Surgery (N, %)a
|
|
Yes
|
3 (20.0)
|
3 (20.0)
|
4 (26.7)
|
10 (22.2)
|
|
No
|
12 (80.0)
|
12 (80.0)
|
11 (73.3)
|
35 (77.8)
|
|
Re-excision (N, %)
|
|
Yes
|
2 (13.3)
|
1 (6.7)
|
3 (20.0)
|
6 (13.3)
|
|
No
|
13 (86.7)
|
14 (93.3)
|
12 (80.0)
|
39 (86.7)
|
- SD standard deviation, IDC invasive ductal carcinoma, ILC invasive lobular carcinoma, IMC invasive mammary carcinoma, ER estrogen receptor, PR progesterone receptor, HER2 Human epidermal growth factor receptor 2, DCIS ductal carcinoma in situ
- amargin revision not guided by fluorescence imaging
